CoDa Therapeutics, Inc.
CoDa Therapeutics is a biopharmaceutical company focused on the development and commercialization of a new generation of wound care therapeutics known as “gap junction modulators.”
The company’s Gap Junction Modulation technology targets the cell-to-cell communication that leads, amongst other things, to cell death in the initial phases of wound-healing following an injury.
> All News
CoDa Therapeutics Receives Orphan Drug Designation for Nexagon® for the Treatment of Persistent Corneal Epithelial Defects
11 May 2009CoDa Therapeutics, Inc. today announced that its lead drug product candidate, Nexagon® has received Orphan Drug Designation from the U.S Food and Drug Administration for the treatment of persistent corneal epithelial defects.....
More...